NBB

The one thing about Don is that he does get the financings done...one way or another...favourable or not. He does seem to try to avoid diluton and as with RVX and 3rd Capital sometimes has to pay the price but to me that is a signal of his confidence in the science (in that case apabetalone) and his efforts to avoid dilution (not withstanding the Bloom Burton debacle).

I just had a look at the page 17 graph from the Biotech Europe and out of the 28 patients in the trial we have 3 approaching the target of 32 weeks which is 14 weeks beyond SOC and the 3 super stars at 56 weeks. I'd love to hear about the quality of life factors for these patients.

Then in terms of dreaming just imagine if the 6 patients continue without progression of mCRPC and if at some point Zenith scientists gain an understanding if the MOA for these people and if they form a definable segment based on some sort of functional medical screening...then we have a market.

Anyway, I have little doubt that Don will get the $25 million financing done.

What happened to Dart/Eastern? Did he get gun shy with his California biotech shut down?

As I've stated previously I don't think a sale is near in time (would be great if zen3694 and related compounds were sold at a good price...but?) yet obvioulsy the Zenith team from a scientific and business POV know much more that I do, so anything is possible.

GLTA

Toinv